Medical Management for Bilateral Grade II Nasal Polyposis with Rhinorrhea
Start with intranasal corticosteroids twice daily as first-line therapy, specifically mometasone furoate 200μg or fluticasone propionate 400μg administered twice daily for at least 12-16 weeks. 1
First-Line Treatment: Intranasal Corticosteroids
Intranasal corticosteroids are the cornerstone of medical management for grade II nasal polyps. The evidence strongly supports twice-daily dosing over once-daily for optimal symptom control, particularly for rhinorrhea and nasal obstruction 2, 1.
Specific regimens proven effective:
- Mometasone furoate nasal spray (MFNS): 200μg twice daily significantly improves nasal obstruction and anterior rhinorrhea within 4 weeks, with continued improvement through 16 weeks 1
- Fluticasone propionate: 400μg twice daily shows significant polyp size reduction and symptom improvement at 4,8, and 12 weeks 1
The twice-daily dosing is critical because it specifically addresses postnasal drip and rhinorrhea more effectively than once-daily administration 1. For grade II polyps, topical corticosteroids can be instilled effectively since the nasal passages are not completely obstructed 3.
Second-Line: Short Course Oral Corticosteroids
If symptoms persist after 4 weeks of intranasal corticosteroids, add a short course of oral prednisone 50mg daily for 14 days, then continue maintenance intranasal corticosteroids. 1
This approach is supported by high-quality evidence showing:
- Significant improvement in disease severity, nasal obstruction, and rhinorrhea at 2 weeks 1
- Reduction in polyp size that persists when followed by maintenance intranasal corticosteroids 2
- The beneficial effects of oral steroids are maintained by subsequent intranasal corticosteroid therapy 2
Critical caveat: Oral corticosteroids alone without maintenance intranasal therapy lead to recurrence. The combination strategy is essential 2.
Add-On Therapy: Leukotriene Modifiers
Consider adding montelukast 10mg daily to intranasal corticosteroids if rhinorrhea and other symptoms remain inadequately controlled after 8-12 weeks. 1, 2
The evidence shows:
- Montelukast added to intranasal corticosteroids provides additional benefit for total symptoms, sense of smell, and rhinorrhea in some studies 1
- Subjective improvement in nasal polyp symptoms when used as add-on therapy 2
- However, one high-quality 2018 study showed no significant difference when added to mometasone 1, suggesting variable response
When to use: Reserve for patients with concurrent asthma or aspirin-exacerbated respiratory disease, where the evidence is stronger 2.
Treatment Algorithm
Weeks 1-4:
- Start MFNS 200μg or fluticasone propionate 400μg twice daily
- Assess response at 4 weeks
If inadequate response at 4 weeks:
- Add oral prednisone 50mg daily for 14 days
- Continue intranasal corticosteroids twice daily throughout and after
If inadequate response at 8-12 weeks:
- Add montelukast 10mg daily (especially if asthma present)
- Continue intranasal corticosteroids twice daily
Maintenance:
- Continue intranasal corticosteroids twice daily long-term to prevent recurrence 1
Important Considerations
Delivery technique matters: Ensure proper head positioning for intranasal corticosteroids to reach the middle meatus where polyps originate. The patient should tilt head forward (looking at feet) while spraying to optimize drug deposition 4.
Duration of therapy: Grade II polyps require at least 12-16 weeks of continuous intranasal corticosteroid therapy to achieve maximal benefit 1. Shorter courses are inadequate.
Monitoring: Reassess polyp size and symptoms at 4,8, and 12 weeks. If no improvement by 12 weeks despite optimal medical therapy, consider referral for endoscopic sinus surgery 5, 4.
Underlying conditions to evaluate: Check for aspirin-exacerbated respiratory disease (AERD), asthma, allergic rhinitis, and immunodeficiency, as these affect treatment response and may require additional interventions 2, 5, 4.
Adverse effects: Intranasal corticosteroids are generally safe with mild epistaxis being the most common side effect (11% of patients) 1. Short courses of oral corticosteroids can cause insomnia, mood changes, and gastrointestinal symptoms 1.